Finpocalypse

As of its latest SEC filing (period ending 2026-03), CME carries a trailing twelve-month P/E of 20.9× and a P/S of 13.2×. That P/E sits near the cheap end of its 10-year range (10-year median 25.5×), meaning the market is currently paying less for each dollar of CME earnings than it typically has over the past decade.

Over the trailing year, CME grew revenue +7.5% and earnings per share +17.1%. Finpocalypse assigns CME a composite valuation grade of A-, scoring its current multiples, growth, and balance-sheet quality against its own history. Every metric here is computed from SEC EDGAR filings, so you can audit the underlying 10-K and 10-Q numbers yourself.

A price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of CME's annual profit; price-to-sales (P/S) does the same against revenue. A single multiple in isolation says little — a “high” P/E can be normal for a fast grower. Finpocalypse instead plots CME's multiple against its own ten-year percentile bands, so you see whether today's valuation is cheap, average, or rich relative to how the market has historically priced this specific company.

Every number is reconstructed from CME's SEC EDGAR 10-K (annual) and 10-Q (quarterly) filings — trailing-twelve-month net income and revenue divided by split-adjusted shares — and refreshes automatically after each new filing. There is no analyst opinion, price target, or paywall: just auditable filing data and the percentile context to interpret it.